Biomira's Revenues Rise In 2nd Qtr
Biomira of Canada announced an increase in revenues for the second quarter of 1996 of 26% to C$2.32 million ($1.7 million). The net loss for the quarter was C$5.5 million or C$ 0.15 per share.
For the six-month period, the firm achieved revenues of C$4 million, up 12.3%. The net loss was C$10.8 million and the loss per share was C$0.30.
The firm said that major milestones highlighting the second quarter were the US launch of Truquant BR blood test and the filing of a Canadian New Drug Submission for the Tru-Scint AD imaging agent. Also, during the second quarter 5.01 million common share warrants were exercised, resulting in cash proceeds of C$28.8 million dollars.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze